Chapter 32 Neurologic Disorders in Cheetahs and Snow Leopards
Worldwide, cheetahs (Acinonyx jubatus) in captivity develop a number of health problems rarely observed in free-ranging cheetahs and unusual in other species, especially felids. These include diseases of the central nervous system (CNS) as well as non-CNS diseases. Among the neurologic diseases, cheetah ataxia, caused by a degenerative spinal cord disorder affecting young and adult cheetahs, represents a serious threat to a sustainable captive cheetah population in Europe. Furthermore, several cases of feline spongiform encephalopathy have been diagnosed in European cheetahs. Although the disease has been reported in several large cat species, the relatively high incidence in cheetahs suggests that they may be more susceptible than other zoo felids. In North America, leukoencephalopathy is an emerging neurologic disease of unknown cause and has had a major impact on the Species Survival Plan (SSP) captive breeding program through loss of important founders.
NEUROLOGIC DISEASES IN CHEETAHS
Cheetah Myelopathy
The cheetah myelopathy is a new and unusual neurologic disease characterized by degenerative lesions of the spinal cord and causing ataxia and paresis. It has emerged in the past 20 years in the European Endangered Species Program (EEP) cheetah population and represents a serious threat to a sustainable captive European cheetah population.28 To date, more than 60 cases have been registered in at least 16 different locations in Europe and in Dubai (United Arab Emirates), resulting in the euthanasia of numerous cheetahs that were part of the EEP breeding program. This disease accounts for 25% of all deaths in the European cheetah population and represents a limiting factor in the growth of the European captive population. Cheetahs of every age group are affected, and often several or all cheetahs of the same litter will eventually develop the disease, either simultaneously or successively over several months or years.
The etiology of the cheetah myelopathy is still unknown, and several causes have been considered, including genetic, environmental, toxic, nutritional (especially copper), and viral factors. Further characterization of the lesion using molecular biologic techniques, as well analytic and epidemiologic investigations of the environmental status of captive cheetahs (e.g., nutrition, standard medication) are in process and may provide clues to the pathogenesis of this unique disease entity.
Clinical Signs
As previously stated, the course of the disease is variable; the initial ataxia and paresis may develop rapidly to hind limb paralysis and recumbency or may progress slowly and stabilize with mild symptoms for several months or years. Although clinical improvement after tentative treatment was observed in a few cases, relapsing bouts of ataxia or paresis eventually reappeared in most cases. Throughout the disease progression, the affected cheetahs had a normal appetite, did not seem to experience pain, remained alert, and responded to visual and auditory stimuli.14,26,27,29
Epidemiology
To date, more than 60 cases have been recognized in at least 16 different institutions, including zoologic parks and private owners. The first cases of cheetah ataxia were described in South Africa in 1981,3 but since then, the syndrome has been reported only in Europe and the United Arab Emirates. Some anecdotal evidence from wild-caught cubs in Namibia has been reported.9 All affected cheetahs have been captive-bred in a European, Middle Eastern, or South African institutions from captive-borne or wild-caught parents, belonging to the South African subspecies (Acinonyx jubatus jubatus) or East African subspecies (Acinonyx jubatus soemmeringii). All affected cheetahs were born from parents without prior clinical neurologic signs. Some of the parents were known to have produced other healthy litters before or after the ataxic litters, and individual parents developed ataxia themselves at a later stage. Often, several or all cubs or siblings from a same litter were affected, with symptoms starting simultaneously in all individuals or developing successively over several months or years. There is no apparent gender predilection, and the age of onset of the ataxia ranges from 2.5 months to 12 years.
Vaccination and deworming of the young and adult cheetahs are routine in all institutions that have reported ataxic animals. A few cubs developed clinical signs before vaccination, but most of the affected cheetahs were routinely vaccinated against feline parvovirus (FPV), FHV-1, and feline coronavirus (FCV) using inactivated or modified live vaccines.14,26,29 Some individuals were also vaccinated against feline leukemia virus (FeLV). Known products used for deworming include ivermectin, mebendazole, fenbendazole, febantel, pyrantel pamoate for cubs, pyrantel tartrate, and fipronil.
Clinical Pathology and Ancillary Procedures
Thorough clinical investigations have been carried out in most reported ataxia cases. Although the cheetah myelopathy has often been temporally associated with clinical herpesvirus infection in cubs, no definitive etiologic factor could be determined.14,26,27,29 Plain radiographs, contrast myelography, and magnetic resonance imaging (MRI) were normal. No abnormalities were detected in the cerebrospinal fluid (CSF) or in the urine.
Hematology and blood chemistry values were always within the normal range. Serum copper values (6-22 μmol/L) revealed no significant difference between ataxic cheetahs and domestic dogs and cats. Furthermore, there was no significant difference in liver copper levels between ataxic cheetahs (4.6 ±3 ppm) and cheetahs without CNS disease (4.3 ±1.5 ppm). However, a significant difference in liver copper has been shown between cheetahs and dogs and cats, but not a wild lynx.29 This difference might be explained by the domestic animals being mostly fed with supplemented commercial food.
Serologic examinations revealed negative or low titers against feline infectious peritonitis (FIP), canine distemper virus (CDV), FPV, FCV, FeLV, feline immunodeficiency virus (FIV), Borna disease virus (BDV), encephalomyocarditis virus, tick-borne encephalitis virus, mucosal disease complex virus, Teschen-Talfan disease virus, Listeria monocytogenes, and Chlamydophila psittaci. Antibody titers against FHV-1 and Toxoplasma gondii were elevated in several cases but negative in another institution, although the cubs had shown ocular discharge and mucopurulent conjunctivitis.14 The tests for FIP were also negative.26
A herpesvirus was isolated from the eyes and nose of one cub with ocular discharge, and the gene sequence showed 99% overlap with FHV-1.29
Pathology
The pattern, distribution, and severity of histologic lesions vary among individuals. Lesions are most prominent from the distal cervical to midthoracic segments, gradually decreasing in severity toward the craniocaudal direction. The degenerative changes are always bilaterally symmetric and often affect the entire circumferential length of lateral and ventral spinal cord funiculi, involving both ascending and descending tracts. The proper fascicle usually is largely spared, and the dorsal tracts are affected only in a few cases, generally older animals. The degenerative lesions are characterized by ballooning of myelin sheaths, either devoid of axons or containing intact or fragmented axons or macrophages (gitter cells, myelinophages). On the longitudinal sections, intact or slightly swollen axons are often seen within dilated myelin sheaths. Spheroids are observed rarely. Depending on the severity and duration of the lesions, myelin sheath vacuolation is associated with varying degrees of astrogliosis, characterized by gemistocytes and proliferation of fibrous processes. Considering the presence of intact axons within dilated myelin sheaths, the lack of features typical for early axonal degeneration, and the excess of myelin loss compared with axonal degeneration, the white matter lesion has been classified as a primary myelin disorder.26,29 However, based on ultrastructural studies, other authors suggest that demyelination must be considered secondary to axonal degeneration.14